Trending...
- wine2wine Vinitaly Business Forum 2025: Equipping the wine industry with the tools to face an uncertain future - 141
- September Career Reset - How Job Seekers Are Using WIOA to Pivot Before Year-End - 111
- CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs - 109
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Mondo named endorsed turf partner by United States Padel Association
- The Emotional Weight of Foreclosure—and Why No One Should Go Through It Alone
- Chicago: Mayor Brandon Johnson Announces Request for South Lawndale Small Business Storefront Activation Project
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
- NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
- Sci-Fi Author Don Viecelli Introduces Alien Times - Book 3, Retribution
- Poncho Tha Popstar: The West's Next King
- Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
- Thorn Ridge® Creates a World of Legends & Lore
- Twice the Laughs: Comedy Star Don Barnhart Rotates Residency at Both Delirious Comedy Club Locations in Las Vegas
- Faith Center Freeport Hosts DJ Lyfe's Music Launch Event
- Schneider Electric Reinforces Commitment to Electrical Contractors with Innovation and Thought Leadership at NECA 2025
- Your Body Isn't Broken—It's Out of Balance: The New Book Revealing the Blueprint to Restore Hormone Balance, Sleep, Gut & Metabolic Health
- Chicago: Mayor Brandon Johnson Celebrates 10-Year Anniversary Of Dyett High School Hunger Strike
- Mayor Brandon Johnson Launches Protecting Chicago Website
- Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
- How Rising Property Taxes Are Pushing Families Toward Foreclosure --4Closure Rescue LLC Responds
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025
- Prostate Cancer Survivor's Podcast Grows Audience And Builds Marketing Muscle
- CCHR, a Mental Health Watchdog Organization, Hosts Weekly Events Educating Citizens on Important Mental Health Issues
- Goat Skin Chicago Partners With Inkdnylon Custom Apparel to Strengthen Brand Growth
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience